Study guide

9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization

Key Takeaways Explain This Topic AI

The ACC/AHA cardiovascular algorithm identifies active cardiac conditions (unstable angina, decompensated heart failure, significant severe arrhythmias, and severe symptomatic aortic stenosis) that necessitate delay or cancellation of elective noncardiac surgery for urgent medical optimization.

The Revised Cardiac Risk Index (RCRI / Lee Criteria) scores 6 independent variables (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, preop insulin therapy, and preop creatinine >2.0 mg/dL); ≥3 risk factors correlates with an 11% risk of major adverse cardiac events (MACE).

The STOP-Bang questionnaire screens for obstructive sleep apnea (OSA); a score ≥5 indicates high risk of moderate-to-severe OSA, mandating opioid-sparing multimodal analgesia, regional techniques, and postoperative continuous positive airway pressure (CPAP).

Smoking cessation timing has biphasic physiological benefits: 12–24 hours reduces carboxyhemoglobin levels (t1/2 = 4–6 hours on room air) and normalizes the oxyhemoglobin dissociation curve (P50); >4–8 weeks is required to decrease sputum volume, restore tracheobronchial ciliary clearance, and significantly reduce postoperative pulmonary complications (PPCs).

Routine, unselective preoperative laboratory testing (CBC, BMP, coagulation, ECG, chest radiograph) in healthy asymptomatic patients does not improve outcomes and is not recommended; diagnostic testing must be driven by clinical history, physical findings, and procedural invasiveness.

Last updated: August 2026

9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization

Perioperative cardiovascular and pulmonary complications are leading causes of morbidity, prolonged hospitalization, and mortality after noncardiac surgery. An evidence-based risk assessment allows the anesthesia provider to identify high-risk patients, initiate targeted preoperative optimization, guide intraoperative monitoring, and plan appropriate postoperative disposition.

1. ACC/AHA Perioperative Cardiovascular Evaluation Algorithm

The American College of Cardiology / American Heart Association (ACC/AHA) guidelines establish a stepwise algorithmic approach to assess cardiovascular risk prior to noncardiac surgery. +-------------------------------------------------------------------------+

  • | ACC/AHA STEPWISE CARDIAC EVALUATION PATHWAY |
  • +-------------------+-----------------------------+-----------------------+
  • | Step 1: Urgency | Step 2: Active Conditions | Step 3: Risk & METs |
  • | - Emergency: | - Unstable angina | - Low risk (<1%): Go |
  • | Proceed to OR | - Decompensated HF | - Elevated risk + |
  • | - Elective: | - Significant arrhythmia | METs >=4: Go |
  • | Evaluate Active | - Severe symptomatic AS | - METs <4: RCRI & |
  • | Conditions | --> CANCEL/OPTIMIZE FIRST | selective testing |
  • +-------------------+-----------------------------+-----------------------+
  • Step 1: Surgical Urgency

Emergency Surgery: If the procedure is an emergency (life or limb threatening), proceed immediately to the operating room with appropriate invasive hemodynamic monitoring, perioperative surveillance, and postop optimization.

Elective / Urgent Surgery: Proceed to Step 2.

Step 2: Active Cardiac Conditions (The "Big 4" Red Flags)

If any of the following active cardiac conditions are present, elective noncardiac surgery must be cancelled or delayed for urgent cardiology consultation, diagnostic evaluation, and medical therapy:

Unstable Coronary Syndromes:

Unstable or severe angina (Canadian Cardiovascular Society [CCS] Class III or IV).

Recent myocardial infarction within 30 days with evidence of ongoing ischemic risk.

Decompensated Heart Failure:

New-onset heart failure, worsening chronic heart failure, or New York Heart Association (NYHA) Functional Class IV dyspnea at rest, paroxysmal nocturnal dyspnea, or pulmonary edema.

Significant Cardiac Arrhythmias:

High-grade atrioventricular block (Mobitz Type II second-degree AV block, third-degree / complete heart block).

Symptomatic ventricular arrhythmias.

Supraventricular tachyarrhythmias (including atrial fibrillation) with uncontrolled, rapid ventricular response ( H R > 100 bpm HR > 100\text{ bpm} H R > 100 bpm at rest).

Symptomatic bradycardia or newly recognized ventricular tachycardia.

Severe Symptomatic Valvular Heart Disease:

Severe Aortic Stenosis: Characterized by aortic valve area < 1.0 cm 2 <1.0\text{ cm}^2 < 1.0 cm 2 , mean transvalvular pressure gradient > 40 mmHg >40\text{ mmHg} > 40 mmHg , or peak aortic jet velocity > 4.0 m/s >4.0\text{ m/s} > 4.0 m/s , accompanied by classic triad symptoms: angina, syncope, or dyspnea . Severe symptomatic AS carries a catastrophic risk of sudden perioperative cardiac collapse and warrants surgical or transcatheter aortic valve replacement (TAVR) prior to elective noncardiac surgery.

Severe Symptomatic Mitral Stenosis: Mitral valve area < 1.5 cm 2 <1.5\text{ cm}^2 < 1.5 cm 2 with pulmonary hypertension or heart failure.

Step 3: Surgical Risk & Functional Capacity Assessment

If active cardiac conditions are excluded, surgical procedural risk is categorized based on expected 30-day Major Adverse Cardiac Event (MACE) risk (death or nonfatal MI):

Low-Risk Procedures ( < 1 % <1\% < 1% MACE Risk): Ambulatory surgery, superficial surgery, cataract extraction, breast surgery, endoscopy. Patients can proceed directly to surgery without further cardiac testing .

Elevated-Risk Procedures ( ≥ 1 % \ge 1\% ≥ 1% MACE Risk): Intraperitoneal, intrathoracic, vascular, major orthopedic, or major urologic/gynecologic procedures.

Assess functional capacity: If functional capacity is ≥ 4 METs \ge 4\text{ METs} ≥ 4 METs without symptoms, proceed to surgery.

If functional capacity is < 4 METs <4\text{ METs} < 4 METs or unknown , evaluate clinical risk factors using the Revised Cardiac Risk Index (RCRI).

2. Revised Cardiac Risk Index (RCRI / Lee Criteria)

The RCRI is the most widely utilized and validated clinical risk prediction tool for perioperative cardiac morbidity in noncardiac surgery. It assigns 1 point for each of 6 independent clinical predictors.

The 6 Independent RCRI Predictors

  • Variable Clinical Definition & Criteria
  • 1. High-Risk Surgery Intraperitoneal, intrathoracic, or suprainguinal vascular procedures

2. Ischemic Heart Disease History of myocardial infarction, positive exercise stress test, current angina, use of sublingual nitroglycerin, or pathologic Q waves on ECG

3. Congestive Heart Failure History of heart failure, pulmonary edema, paroxysmal nocturnal dyspnea, bilateral crackles, S3 gallop, or pulmonary vascular redistribution on CXR

4. Cerebrovascular Disease History of transient ischemic attack (TIA) or ischemic/hemorrhagic cerebrovascular accident (CVA)

5. Diabetes on Insulin Preoperative treatment with subcutaneous insulin therapy

6. Renal Impairment Baseline preoperative serum creatinine > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL ( > 177 μ mol/L >177\ \mu\text{mol/L} > 177 μ mol/L )

RCRI Risk Stratification & 30-Day MACE Rates

  • RCRI Score RCRI Class 30-Day MACE Risk (Cardiac Death, MI, Cardiac Arrest)
  • 0 Points Class I 0.4 − 0.5 % 0.4 - 0.5\% 0.4 − 0.5% (Low Risk)
  • 1 Point Class II 0.9 − 1.0 % 0.9 - 1.0\% 0.9 − 1.0% (Low-Intermediate Risk)
  • 2 Points Class III 4.0 − 6.6 % 4.0 - 6.6\% 4.0 − 6.6% (Moderate Risk)
  • ≥ 3 \ge 3 ≥ 3 Points Class IV > 9.0 − 11.0 % >9.0 - 11.0\% > 9.0 − 11.0% (High Risk)

NCE Management Guideline: If an elevated-risk surgical patient has poor functional capacity ( < 4 METs <4\text{ METs} < 4 METs ) and elevated RCRI score ( ≥ 2 \ge 2 ≥ 2 predictors) , pharmacologic stress testing (dobutamine stress echocardiography or dipyridamole/adenosine myocardial perfusion imaging) is recommended only if the results will change clinical management (e.g., cancel elective surgery, trigger coronary revascularization, or alter monitoring strategy).

3. Postoperative Pulmonary Complications & The ARISCAT Score

Postoperative pulmonary complications (PPCs)—including atelectasis, pneumonia, acute respiratory failure, bronchospasm, and aspiration pneumonitis—occur in up to 5–10% of all noncardiac surgical patients and rival cardiac complications in incidence and cost.

The ARISCAT Risk Model (Canet et al.)

The ARISCAT (Assess Respiratory Risk in Surgical Patients in Catalonia) score calculates PPC risk based on 7 independent factors:

Age: ≤ 50 yrs \le 50\text{ yrs} ≤ 50 yrs (0 pts), 51 − 80 yrs 51-80\text{ yrs} 51 − 80 yrs (3 pts), > 80 yrs >80\text{ yrs} > 80 yrs (16 pts).

Preoperative S p O 2 SpO_2 Sp O 2 ​ on Room Air: ≥ 96 % \ge 96\% ≥ 96% (0 pts), 91 − 95 % 91-95\% 91 − 95% (8 pts), ≤ 90 % \le 90\% ≤ 90% (24 pts).

Respiratory Infection in Past Month: Yes (17 pts).

Preoperative Anemia ( H b ≤ 10 g/dL Hb \le 10\text{ g/dL} H b ≤ 10 g/dL ): Yes (11 pts).

Surgical Incision Site: Peripheral (0 pts), Upper abdominal (15 pts), Intrathoracic (24 pts).

Duration of Surgery: ≤ 2 hours \le 2\text{ hours} ≤ 2 hours (0 pts), 2 − 3 hours 2-3\text{ hours} 2 − 3 hours (16 pts), > 3 hours >3\text{ hours} > 3 hours (23 pts).

Emergency Surgery: Yes (8 pts).

ARISCAT Risk Tiers: Low risk ( < 26 pts <26\text{ pts} < 26 pts , PPC risk ≈ 1.6 % \approx 1.6\% ≈ 1.6% ); Intermediate risk ( 26 − 44 pts 26-44\text{ pts} 26 − 44 pts , PPC risk ≈ 13.3 % \approx 13.3\% ≈ 13.3% ); High risk ( ≥ 45 pts \ge 45\text{ pts} ≥ 45 pts , PPC risk ≈ 42.1 % \approx 42.1\% ≈ 42.1% ).

4. Obstructive Sleep Apnea (OSA) & The STOP-Bang Screening Tool

Undiagnosed obstructive sleep apnea is highly prevalent among surgical patients. Repetitive upper airway collapse during sleep produces nocturnal hypoxemia, hypercapnia, systemic and pulmonary hypertension, polycythemia, and biventricular strain. Anesthetic agents, sedatives, and opioids exacerbate upper airway collapsibility and suppress arousal reflexes. +-------------------------------------------------------------------------+

  • | THE STOP-BANG SCREENING CRITERIA |
  • +-------------------------------------------------------------------------+
  • | S - Snoring: Do you snore loudly (louder than talking/through door)? |
  • | T - Tired: Do you often feel tired, fatigued, or sleepy during daytime? |
  • | O - Observed: Has anyone observed you stop breathing during sleep? |
  • | P - Pressure: Do you have or are you being treated for hypertension? |
  • | B - BMI: Body Mass Index > 35 kg/m²? |
  • | A - Age: Age > 50 years? |
  • | N - Neck Circumference: > 43 cm (17 in) male, > 40 cm (16 in) female? |
  • | G - Gender: Male? |
  • +-------------------------------------------------------------------------+
  • STOP-Bang Risk Stratification

Low Risk: 0 – 2 points (High negative predictive value for moderate/severe OSA).

Intermediate Risk: 3 – 4 points.

High Risk of Moderate-to-Severe OSA:

  • Score ≥ 5 \ge 5 ≥ 5 points , OR
  • ≥ 2 \ge 2 ≥ 2 "STOP" criteria positive PLUS Male gender , OR
  • ≥ 2 \ge 2 ≥ 2 "STOP" criteria positive PLUS BMI > 35 kg/m 2 >35\text{ kg/m}^2 > 35 kg/m 2 , OR

≥ 2 \ge 2 ≥ 2 "STOP" criteria positive PLUS Neck circumference > 43 cm >43\text{ cm} > 43 cm (male) / > 40 cm >40\text{ cm} > 40 cm (female) .

Perioperative Anesthetic Management of High-Risk OSA Patients

Preoperative: Instruct patients to bring their home continuous positive airway pressure (CPAP) machine to the surgical center on the day of surgery.

Intraoperative: Utilize regional anesthesia or peripheral nerve blocks whenever feasible. For general anesthesia, avoid or minimize long-acting opioids; employ multimodal analgesia (acetaminophen, ketorolac, ketamine, dexmedetomidine, lidocaine infusions). Elevate head of bed / ramp position for preoxygenation, induction, and extubation.

Postoperative: Fully reverse neuromuscular blockade (document TOF ratio > 0.9 >0.9 > 0.9 or utilize sugammadex). Extubate only when fully awake and following commands. Initiate immediate postop CPAP in recovery.

5. Smoking Cessation Physiology & Perioperative Time Course

Cigarette smoking exposes the body to thousands of toxic compounds, principally carbon monoxide, nicotine, cyanide, and particulate irritants. Understanding the exact physiological time course of smoking cessation is a heavily tested NBCRNA topic. +-------------------------------------------------------------------------+

  • | PHYSIOLOGICAL TIMELINE OF SMOKING CESSATION |
  • +--------------------+----------------------------+-----------------------+
  • | 12 - 24 Hours | 1 - 2 Weeks | > 4 - 8 Weeks |
  • | - CO elimination | - Decreased airway | - Normal ciliary beat |
  • | - P50 shifts right | hyperreactivity | - Sputum vol drops |
  • | - Nicotine drops | - Transient cough increase | - PPCs significantly |
  • | - HR & BP normalize| - Sputum mobilization | reduced |
  • +--------------------+----------------------------+-----------------------+
  • Time Course of Smoking Cessation

Cessation Interval Physiological Changes Clinical Impact

12 to 24 Hours - Carbon monoxide elimination: CO half-life is 4 − 6 hours 4 - 6\text{ hours} 4 − 6 hours on room air ( < 1 hour <1\text{ hour} < 1 hour on 100 % O 2 100\%\ O_2 100% O 2 ​ ). Carboxyhemoglobin levels fall from 5 − 15 % 5-15\% 5 − 15% in active smokers to < 1 − 2 % <1-2\% < 1 − 2% .; - Oxyhemoglobin curve shift: Removal of CO shifts the oxyhemoglobin dissociation curve to the RIGHT (restores P50 toward normal 26.8 mmHg 26.8\text{ mmHg} 26.8 mmHg ), dramatically improving oxygen unloading to tissues.; - Nicotine clearance: Nicotine half-life is 1 − 2 hours 1 - 2\text{ hours} 1 − 2 hours ; elimination reduces sympathetic tone, lowering heart rate, blood pressure, and systemic vascular resistance. Immediate improvement in myocardial oxygen supply/demand balance; enhanced tissue oxygen delivery.

1 to 2 Weeks - Airway secretions become mobilized.; - Bronchial hyperreactivity begins to decrease.; - Transient increase in cough and sputum: As cilia begin unparalyzing, patients may cough more frequently. Decreased risk of acute intraoperative bronchospasm during airway instrumentation.

> 4 > 4 > 4 to 8 Weeks - Tracheobronchial clearance normalization: Ciliary column architecture and beating frequency fully recover.; - Sputum volume and viscosity significantly decrease.; - Immune and macrophage phagocytic activity in alveolar spaces normalize.; - Hepatic enzyme induction (CYP1A2) returns toward baseline. Significant reduction in Postoperative Pulmonary Complications (PPCs) , including atelectasis, pneumonia, and prolonged mechanical ventilation.

NCE Pearl — The Old "48-Hour Cessation Paradox": Historical dogma suggested that stopping smoking 24–48 hours preoperatively was harmful due to increased mucus plugging and uncoordinated ciliated clearance. Modern evidence confirms that stopping smoking at ANY time prior to surgery is beneficial : 12–24 hours optimizes oxygenation and cardiovascular parameters, while > 4 − 8 >4-8 > 4 − 8 weeks optimizes pulmonary parenchyma and reduces PPCs.

6. Evidence-Based Indications for Preoperative Diagnostic Testing

Routine, untargeted screening tests ("routine panel batteries") in healthy, asymptomatic patients are wasteful, generate false positives, and fail to alter management or improve clinical outcomes. Preoperative testing must be ordered selectively based on specific clinical indications.

Indication Matrix for Diagnostic Tests

Diagnostic Test Evidence-Based Indications When NOT Indicated

12-Lead ECG Known coronary artery disease, significant arrhythmia, peripheral vascular disease, structural heart disease, or elevated-risk surgery in patients with ≥ 1 \ge 1 ≥ 1 RCRI risk factor Asymptomatic patients undergoing low-risk procedures (e.g., eye surgery, superficial excision)

Transthoracic Echo (TTE) Unexplained dyspnea, suspected undiagnosed severe murmur (suspected severe AS), worsening heart failure symptoms, or known cardiomyopathy without recent echo within 12 months Routine assessment in stable, asymptomatic patients with stable chronic disease

Chest Radiography (CXR) New or unstable cardiopulmonary symptoms (acute cough, hemoptysis, fever, severe dyspnea), acute respiratory infection, or severe thoracic pathology Routine screening in asymptomatic patients or stable COPD/asthma

Complete Blood Count (CBC) Expected significant surgical blood loss ( > 500 mL >500\text{ mL} > 500 mL ), known anemia, hematologic disorder, chronic kidney disease, or chemotherapy Healthy patients undergoing low-risk, minimally invasive procedures

Serum Electrolytes & Creatinine Hypertension, diabetes, chronic kidney disease, heart failure, liver disease, or use of ACEi/ARBs, diuretics, or digoxin Healthy asymptomatic individuals undergoing minor surgery

Coagulation Studies (PT/INR, aPTT) Patients receiving anticoagulants (warfarin, heparin), known coagulopathy, liver disease, or active bleeding history Routine screening prior to regional or general anesthesia without bleeding history

Loading diagram... ACC/AHA Cardiac Assessment & RCRI Stratification Algorithm